Phase 1 Study of KHK2823 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs KHK 2823 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors Kyowa Kirin
- 31 Jul 2019 Status changed from active, no longer recruiting to discontinued.
- 08 Jul 2019 Planned primary completion date changed from 31 Mar 2019 to 31 Jul 2019.
- 01 Jul 2019 Planned End Date changed from 31 May 2019 to 31 Jul 2019.